SHANGHAI, November 10, 2025 — CreatiPhage Biotechnology Co., Ltd. (CreatiPhage) has been selected as a 'Rising Star' on the 2025 Chinese Healthcare Front-Runners Top 100 list, recognizing its leading position and growth potential in phage therapy.
The 2025 Chinese Healthcare Front-Runners Top 100 list was announced on October 31, 2025, at the Shanghai Biopharmaceutical Investment and Financing Summit and Fudan Biopharmaceutical Innovation Development Forum. Initiated by the Shanghai Biomedical Technology Industry Promotion Center, the list has been released annually since 2023 and serves as an industry barometer for frontier trends and technological innovation.
Bacterial antimicrobial resistance (AMR) has become a core threat to modern medicine. Without urgent action, drug-resistant infections could cause 39 million deaths by 2050 and annual economic losses of up to USD 412 billion. According to the World Health Organization's Global Antibiotic Resistance Surveillance Report 2025, resistance to life-saving drugs remains dangerously high and continues to climb, particularly in developing countries. China bears one of the heaviest burdens of drug-resistant bacterial infections.
As vice chair of the Alliance Phage of China, CreatiPhage focuses on developing innovative drugs based on natural and artificial phages, personalized therapies, customized technical services, and consumer-grade products. The company collaborates with dozens of medical institutions on clinical research in phage therapy, undertakes national key special project topics on frontier biotechnology for phage therapy, and has led or participated in the publication of multiple papers, consensus statements, standards, and guidelines in the field.
CreatiPhage has been recognized as a technology-based and innovative SME, secured venture capital from Wenzhou Capital, YS Capital, and Xuhui STI, and was selected as one of the 2023 Shanghai Top 50 Most Investable Startups. This latest recognition on the 2025 Chinese Healthcare Front-Runners Top 100 'Rising Star' list will further drive the company to seize opportunities, confront the hidden pandemic of drug-resistant bacteria, and develop comprehensive phage solutions.
About CreatiPhage
CreatiPhage focuses on developing innovative drugs, personalized therapies, customized technical services, and consumer-grade products based on natural and artificial phages, aiming to address the growing threat of antimicrobial resistance. The company has been recognized as Shanghai’s innovative SME and won first place in the Life Health Subcategory of the 2023 “Maker in China” Shanghai Division.
WeChat Account: 创噬纪CreatiPhage
Website: www.cphage.com
